Hydroxychloroquine in the treatment of COVID-19

COVID-19 is a new illness that can affect your lungs and airways. It's caused by a virus called coronavirus. Coronavirus disease 2019 is an infectious disease caused by severe acute respiratory syndrome coronavirus 2. The disease was first identified in December 2019 in Wuhan, the capital of China's Hubei province, and has since spread globally, resulting in the ongoing 2019–20 coronavirus pandemic. The first confirmed case of what was then an unknown coronavirus was traced back to November 2019 in Hubei province.Common symptoms include fever, dry cough, fatigue, sputum production, loss of smell, and shortness of breath. While the majority of cases result in mild symptoms, some progress to viral pneumonia and multi-organ failure. Emergency symptoms include difficulty breathing, persistent chest pain or pressure, confusion, difficulty waking, and bluish face or lips.
There are no drugs or other therapeutics approved by the Drug Administration to prevent or treat COVID-19. Current clinical management includes infection prevention and control measures and supportive care, including supplemental oxygen and mechanical ventilatory support when indicated. Interim guidelines for the medical management of COVID-19 will be provided soon by the Department of Health and Human Services COVID-19 Treatment Guidelines Panel.
The Journal of Pharmaceutical Sciences & Emerging Drugs is announcing its special issue entitled “Hydroxychloroquine in the Treatment of COVID-19. It aims to spread the scientific information on the C0VID-19 and help the scientific world and researcher for the remedy and upgrading the research. Special issue in this pandemic situation is to increase the quality of the journal, also to enhance the recent developments to prevent Covid 19.
You may Submit manuscripts at https://www.scholarscentral.org/submissions/pharmaceutical-sciences-emerging-drugs.html or an e-mail attachment to the Editorial Office at editor.jpsed@peerjournal.org
Best Regards,
Editorial Assistant
Journal of Pharmaceutical Sciences & Emerging Drugs
E-mail: editor.jpsed@scitechnol.com
What’sapp No.: +1-579-679-8957